Three-month change in PSA as a surrogate endpoint for mortality in advanced hormone-refractory prostate cancer (HRPC): Data from Southwest Oncology Group Study S9916
2004 ◽
Vol 22
(14_suppl)
◽
pp. 4505-4505
2004 ◽
Vol 22
(14_suppl)
◽
pp. 4505-4505
◽
2004 ◽
Vol 22
(14_suppl)
◽
pp. 4510-4510
◽
2004 ◽
Vol 22
(14_suppl)
◽
pp. 4510-4510
◽
1993 ◽
Vol 150
(2 Part 1)
◽
pp. 411-413
◽
1992 ◽
Vol 28
(2-3)
◽
pp. 477-478
◽
2006 ◽
Vol 176
(2)
◽
pp. 548-553
◽